We Help Companies Find New Sales Opportunities
Chemicals & Pharmaceuticals - 2003
William Ransom is to acquire the natural healthcare brands portfolio of J Pickles of Harrogate for £0.6m, but Pickles will continue to manufacture the products under a long-term supply agreement.
Lubrizol is to acquire Avecia Additives, the Manchester-based manufacturer of colour additives with 110 staff, for undisclosed terms.
LGC, the forensic sciences group with about 700 staff, is to be sold by 3i to Legal & General Ventures for £70m.
Cytomyx Holdings is to raise £2m in a share placing to help fund the acquisition of Clinomics Biosciences of the US.
Peter Black Healthcare, the Swadlincote-based manufacturer of vitamin supplements and herbal remedies with 240 staff, has been acquired by Perrigo of the US for undisclosed terms.
Sinclair Pharmaceuticals has raised £22m in a share placing to fund the expansion of its drug development business.
BioProgress is looking to raise £6.6m for the development of a pharmaceutical production plant in Cambridgeshire, having won a contract to supply FMC of the US.
Invest NI is to support a £5.3m project by Kiel Laboratories of the US to set up a prescription medicines plant in Carrickfergus, with the creation of 100 jobs over the next three years.
Galen Holdings has sold its Pharmaceutical Development and Manufacturing Services business to the company's founder and former Chairman for £20m.
Purely Proteins of Cambridge has received a first round of venture funding from Avlar BioVentures and Yorkshire Fund Managers, in order to expand its business providing human proteins for pharmaceutical research.
CeNes Pharmaceuticals has acquired TheraSci, the developer of drugs for the central nervous system, for up to £3.7m.
Duke Street Capital has acquired Accantia, the Birmingham-based toiletries manufacturer, from ABN Amro Capital for £225m.
Cambridge University has won government permission to develop a £24m laboratory for behavioural neuroscience, although it may not be built for some time.
Invista, the DuPont lycra business with about 500 staff in Northern Ireland and 375 in Wilton, is to be acquired by Koch Industries of the US in a £2.7bn deal.
The Specials Laboratory is to relocate its tailor-made pharmaceuticals business to a new £1m site in Northumberland next year, and the 35-strong workforce will expand.
The Welsh Development Agency is in discussions with a number of companies interested in relocating to the newly-completed £3.3m Medi-Science Campus at Gwaun Elai, near Llantrisant.
Transad International has acquired Personal Screening, the supplier of home health testing kits, from Wellbeing Screening for £0.6m.
Chiron of the US is looking to sell its SBL vaccines division in Sweden, in order to help fund a £85m expansion plan that will safeguard 600 jobs at the recently-acquired Powderject plant on Merseyside.
Simon Storage is planning a £98m expansion programme for its bulk chemical storage business, with financial backing from Bank of Scotland, Royal Bank of Scotland and Investec Structured Finance.
Lux Biotechnology has secured about £0.6m of funding from Archangel Informal Investments, in order to expand its research capability, recruit more staff and exploit its biosensor biological detection technology.
Tepnel Life Sciences is to acquire Orchid Diagnostics, the US biotechnology company, for £2.5m.
Astex Technology has acquired MetaGen Pharmaceuticals, a spin-out from Schering, and about eight of MetaGen's 40 staff will transfer from Berlin to Cambridge.
Intercare, the pharmaceuticals manufacturer, is to be acquired by Cardinal Health of the US for £306m.
The Scottish Executive is to provide about £2m of regional selective assistance to PharmaImaging Group to set up a new £15m pharmaceutical research facility in Livingston, with the creation of up to 250 jobs.
Allergy Therapeutics is planning to raise up to £15m in a flotation on Aim over the next 18 months, to fund the development of an allergy vaccine.
Safa Group, the supplier of healthcare and first aid products, is to be acquired by Healthcare Enterprise Group in a £12m deal.
AstraZeneca is to invest £60m in Abgenix, the US biotechnology company, in order to collaborate in the area of antibody drug development.
Spencer Coatings has bought Eagle Industrial Paints of the West Midlands out of receivership.
Lucite International is to build a £60m methyl methacrylate production plant in China, as part of an integrated chemical complex being built in Caojing.
Biocatalysts, the supplier of enzymes to food manufacturers, is to relocate to a new £2m 23,000 sq ft building at Parc Nantgarw in Treforest next year, and expects to double the 26-strong workforce.
Manchester Innovation is to consider a number of rival bids to build a £25m biotechnology centre on the Manchester University campus, including laboratories, offices and conference facilities.
Cambridge Antibody Technology is to sell an 11% equity stake to Genzyme of the US for £23m, as part of a collaboration between the two companies in the development of drugs for fibrotic diseases.
Abbott Laboratories is to create 125 new jobs through the £39m expansion of its Dartford Murex diagnostic treatments manufacturing plant in Kent by the end of next year.
Finance Wales is to support the expansion of MGS Micropure, the Cwmfelinfach-based manufacturer of preservatives for cleaning products, and six new jobs will be created.
Intercare is looking to spend up to £40m on acquisitions to expand its pharmaceutical manufacturing business.
Biotrace International has acquired International BioProducts, the US germ detection company, for £6.4m.
Roche, the Swiss pharmaceuticals group, has awarded a £40m contract to PCM to build a new headquarters for 1,100 staff in Welwyn Garden City by late 2005.
Chemical Synthesis Services is planning to invest £25m in the expansion of the former research and services division of Galen in Craigavon.
Genzyme has won US and European approval to start producing ingredients for a kidney drug at its new £55m plant in Haverhill.
Evolutec has raised a further £0.7m to fund the expansion of its Oxford-based biotechnology business, and hopes to float on Aim next year.
Simbec Research, the Merthyr-based pharmaceuticals research company with 80 staff, has undergone a management buy-out from Merck Sante SAS of France for undisclosed terms.
The Darwin Centre for Biology & Medicine is seeking European funding to build a £15m international science centre in Pembrokeshire, with the creation of 45 jobs.
Hickson & Welch, the Castleford-based chemicals manufacturer with 300 staff, has undergone a £21m management buy-out backed by Dunedin Capital Partners.
Xenova has announced a £8.5m takeover bid for KS Biomedix, and expects to raise at least £9m in a share issue to fund the development of KSB's leading drug.
The School of Tropical Medicine in Liverpool is seeking a £25m grant that would enable it to double in size.
Ineos Chlor has secured a £50m DTI grant to expand its chlorine production plant in Runcorn, which will involve a £389m investment in new equipment.
Onyx Scientific is to create a further 20 jobs at a new pharmaceuticals research laboratory in Sunderland over the next two years, and expects additional investment to provide 120 vacancies over the next seven years.
Powderject's new US parent Chiron is to relocate 12 senior managers from Uxbridge to the Powderject office in Oxford.
Chemring is to sell its Alloy Surfaces chemicals business in the US to Akron Paint & Varnish for up to £2.5m.
Osmetech, the developer of electronic odour sensors, has closed its Crewe headquarters with the loss of 20 jobs, in order to relocate its research and development operation to the US.
CP Pharmaceuticals, the Wrexham-based supplier of drugs to hospitals, has been acquired by Wockhardt of India for £11m.
Axis-Shield has sold its autoimmune diagnostics business to the Euro-Diagnostica Group for £2.2m.
Vernalis is to merge with British Biotech to create a combined biotechnology group with a market capitalisation of £90m, and the staffing levels will be cut from 204 to 130.
Biotrace International has acquired Maltec, the Danish supplier of microbiological and life sciences products, for a nominal sum.
Avecia has agreed to sell its Metal Extraction Products and Intermediates & Stabilizers operations in the US to Cytec for about £60m, which will involve the transfer of 200 staff.
Norgine has raised a further £4.3m to invest in new production lines and improvements at its pharmaceuticals manufacturing plant near Caerphilly, with the creation of 66 jobs.
National Starch & Chemical is to sell its Plasticoat cheese coatings business to DSM for undisclosed terms.
PPL Therapeutics is said to be planning to shed at least 90 jobs at its research facility in Roslin, after partner Bayer stopped a project to develop treatments for lung disorders.
Ferraris is to acquire Bionostics, the US supplier of liquid formulations to test the accuracy of medical diagnostic equipment, for £19m.
Powderject is planning to invest £85m at its vaccine production plant in Liverpool over the next five years, with the creation of an unspecified number of jobs.
Protherics is seeking financial assistance from the Welsh Assembly to expand its biotechnology-based production plant in Llandysul.
AstraZeneca is planning to invest £19m in a new research facility in India to develop treatments for tuberculosis.
Eli Lilly is to set up a European Centre for Neuroscience at Windlesham, Surrey, with the creation of 120 scientific jobs over the next five years.
Eli Lilly is to invest more than £30m in the expansion of its biotechnology production plant in south Liverpool, with the creation of up to 75 new jobs.
Powderject, the vaccine maker, is to be acquired by Chiron of the US for more than £540m.
Evolution Group's IP2IPO intellectual property subsidiary is to invest £5m in companies spun out from King's College London over the next five years, enabling King's to commercialise its expertise in medical research and life sciences.
Angel Biotechnology is seeking a second site in Northumberland to expand its medical research business, with the creation of up to 50 new jobs.
British Biotech is forming an alliance with MerLion Pharmaceuticals of Singapore to develop anti-bacterial treatments from natural products.
Imperial College London is linking up with Bioscience Managers Limited to create a £50m venture capital fund to invest in early-stage medical and life science companies.
Axis-Shield is to relocate its biotechnology laboratory division from Norway to Dundee by the end of the year, with the creation of up to 20 jobs.
Pfizer is to close the Pharmacia drug development centre in High Wycombe with the loss of 164 jobs, although some jobs will be relocated to its site in Kent.
Protherics is to acquire Enact Pharma, the biopharmaceuticals company, for £7.9m, and has also announced plans to raise £3m in a share offer.
Vernalis is planning to raise £14m in a share offer to fund the expansion of its drug development business, while talks are taking place about a possible bid for the company.
PPL Therapeutics has dropped plans to build a £42m biotechnology plant near Edinburgh, and may now outsource its manufacturing operations.
Shire Pharmaceuticals has awarded a $18m contract to AMEC to build a global vaccines research centre at its site in Laval, Canada.
SembCorp Utilities of Singapore has acquired the Enron Teesside Operations chemicals site at Wilton for £83m, securing the future of 579 jobs.
Oxxon Pharmaccines has raised £15m in a private financing exercise to expand its Oxford-based biotechnology business.
Network Health & Beauty, the Farnborough-based distributor of beauty and personal care products with 47 staff, has been acquired by EPIC Brand Investments and the Lornamead Group.
Aroma & Fine Chemicals has secured a £5.7m funding package from the Royal Bank of Scotland to expand its Widnes-based speciality chemicals manufacturing business.
Oxford Glycosciences has recommended that shareholders accept a £101m takeover offer from Celltech.
PPL Therapeutics is to sell its xenograft and stem cell activities to a newly-formed US company called Regenecor Holdings, in which PPL will hold an equity stake.
MedPharma is planning to raise £8.8m in a flotation on Aim next month, in order to fund the expansion of its Oxfordshire-based pharmaceuticals business.
Osmetech has announced a £2.2m deal to acquire Roche's US-based OPTI range of blood gas analysers.
ReNeuron, the biotechnology company, has agreed terms for a £3.6m management buy-out backed by private equity vehicle St James's.
British Vita has acquired Synco, the Italian colour and additive masterbatch producer, from Cognis for £1.3m.
BP is planning to build a £200m purified terephthalic acid production plant at its Geel site in Belgium by 2006, and design work will be carried out by Technip Italy.
BioWisdom has raised £2.5m to fund the expansion of its ontologies business, in which software applications are used to improve access to biomedical information.
ML Laboratories is to sell its Icodextrin glucose polymer manufacturing business in Liverpool to Baxter Healthcare for £6.5m.
British Biotech is to merge with RiboTargets, creating a combined biotechnology group with a market value of £52m.
The East of England Development Agency is promoting the case for the development of a £600m national nanotechnology research centre in Cambridge, and production could be located on Humberside and administration in Cranfield.
Miza Pharmaceuticals has been bought out of administration by a management-led consortium operating under the name of Inyx Pharma, securing 138 jobs at its Runcorn factory.
The Department of Trade & Industry has announced plans for a £30m biosciences facility at the Estuary Business Park on Merseyside, including three laboratories, one production plant and the creation of 1,000 jobs.
Crispin & Borst has won a £1.8m contract to refurbish a chemistry laboratory in Sutton, Surrey, for the Institute of Cancer Research.
Cytomyx has expanded its life sciences business with the £0.1m acquisition from Cytocell of assets for the manufacture of kits utilising DNA probe technology.
Norgine is creating 200 new jobs at its pharmaceuticals plant in Caerphilly, following a recent £8m investment in a packing facility.
Peri-dent is to invest £2m in the expansion of its oral-care products factory in Galashiels, with the creation of up to 60 jobs.
Creightons of West Sussex has bought Nemesis Toiletries out of receivership for £0.2m, saving 85 jobs at the Potter & Moore business in Peterborough.
Alliance UniChem is seeking acquisitions to expand its drugs distribution business in eastern Europe, and is particularly interested in Poland, Russia and the Baltics.
Spencer Coatings has acquired Pearl Paints of Wales out of receivership for a nominal sum, and production will be relocated to Aberdeen.
Distillex, the Leyland-based solvent recovery company with 44 staff, has been acquired by P&R Disposal Services of St Helens for undisclosed terms.
ClinPhone, the clinical trials company, is to expand its Nottingham headquarters into a new 5,843 sq ft office nearby.
Theratase is considering plans to extend its Biozyme Laboratories plant in Blaenavon by 50%, to increase production of enzymes and biochemicals for the diagnostic and pharmaceutical industries.
Dundee University has finalised plans to invest £30m in the development of a new life sciences centre and computing building over the next three years.
Provalis has secured a £1m Welsh Assembly grant to expand production of medical testing kits at its Deeside factory.
Maelor, the Wrexham-based medical research company, is planning to raise £2.9m in a share issue to fund the development of its existing product portfolio, acquire additional products and grow overseas markets.
Fisher Scientific is creating 24 new jobs for development chemists, following the expansion of its chemical manufacturing and distribution operation in Loughborough.
Phoqus Pharmaceuticals has raised £7m to fund the expansion of its tablet manufacturing process, which is designed to prevent drug counterfeiting.
Degussa is to sell speciality chemical operations in Barry, South Wales, and Hythe, Southampton, to Cognis for undisclosed terms, as part of the regulatory agreement for the acquisition of Laporte in 2001.
BP has agreed to sell the Fosroc Mining chemicals division of Burmah Castrol, including 13 manufacturing sites in seven countries, to a management buy-out backed by Close Brothers Private Equity for £32m.
DCC has acquired Shannon Environmental Services, the Irish waste chemical treatment company, for about £4m.
Amarin has raised £13m in a share placing to fund the launch of new biotechnology-based products and expand its neurology sales force.
DuPont UK is to relocate its agricultural division and up to 100 jobs from Stevenage to Milton Keynes by the middle of next year, and its Hemel Hempstead branch will also move there.
ICON has acquired Medeval Group, the Manchester-based provider of clinical pharmacology services to the pharmaceutical industry, for about £10m.
Cambridge Antibody Technology has offered to acquire Oxford Glycosciences for £110m, and the group's combined cash reserve of £260m will be used to license new drugs or acquire another biotechnology company.
The Office of Fair Trading has recommended complete deregulation of the pharmacy market in order to give consumers more choice about where to get NHS prescriptions, which is expected to lead to supermarket groups setting up their own dispensing chemists.
Skyepharma has invested £2.5m in Micap of Newton-le-Willows, in order to investigate the pharmaceutical applications of Micap's micro-encapsulation technology.
United Phosphorus has announced a £10m refinancing package to fund the expansion of its Cheshire-based pesticides business.
Biotica Technology has raised £3m of venture capital to expand its Cambridge-based drug discovery business, which is focusing on polyketide biosynthesis.
BP is to sell Sericol, the speciality printing chemicals business with 1,200 staff worldwide and a factory in Broadstairs, to US investment firm Saratoga Partners for £75m.
Enact Pharma has acquired De Montfort Biopharma of Leicestershire for an initial £0.5m.
Replizyme has raised £1m from investors to expand its drug discovery business in York, and its full-time scientific staff will rise from six to 15.
Medipure is planning to set up a factory in Denbigh to develop new disinfectants for hospitals, with the creation of about 20 jobs over the next two years.